Could it be that the entire biotech analyst community has either believed the lies made by Adam Feuerstein for a decade or that they've decided to not talk about the stock given the risk to their career if they were wrong?
Could it be the Blue Sky laws that prevent institutional investors from buying on OTC?
Could it be the fact that the 60/40 portfolio is dead, bonds are correlated with equities in a downward spiral, and family offices that once speculated on the most dubious sector, biotech, are instead de-risking by taking defensive positions?
These are all reasons why NWBO isn't a $10 billion dollar company right now.
Market Data 
Markets 
AI
